Generic Levulan Kerastick Availability
Last updated on May 7, 2025.
Levulan Kerastick is a brand name of aminolevulinic acid topical, approved by the FDA in the following formulation(s):
LEVULAN (aminolevulinic acid hydrochloride - solution;topical)
-
Manufacturer: SUN PHARM INDS INC
Approval date: December 3, 1999
Strength(s): 20% [RLD]
Is there a generic version of Levulan Kerastick available?
No. There is currently no therapeutically equivalent version of Levulan Kerastick available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Levulan Kerastick. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Methods for photodynamic therapy
Patent 10,357,567
Issued: July 23, 2019
Inventor(s): Lundahl Scott & Guttadauro Michael
Assignee(s): DUSA Pharmaceuticals, Inc.A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.
Patent expiration dates:
- January 12, 2038✓
- January 12, 2038
-
Methods for photodynamic therapy
Patent 11,077,192
Issued: August 3, 2021
Inventor(s): Lundahl Scott & Guttadauro Michael
Assignee(s): DUSA PHARMACEUTICALS, INC.A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.
Patent expiration dates:
- January 12, 2038✓
- January 12, 2038
-
Methods for photodynamic therapy
Patent 11,135,293
Issued: October 5, 2021
Inventor(s): Lundahl Scott & Guttadauro Michael
Assignee(s): DUSA PHARMACEUTICALS, INC.A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.
Patent expiration dates:
- January 12, 2038✓
- January 12, 2038
-
Methods for photodynamic therapy
Patent 11,571,478
Issued: February 7, 2023
Inventor(s): Lundahl; Scott et al.
Assignee(s): DUSA PHARMACEUTICALS, INC. (Billerica, MA)A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.
Patent expiration dates:
- January 12, 2038✓
- January 12, 2038
-
Methods for photodynamic therapy
Patent 11,690,914
Issued: July 4, 2023
Inventor(s): Lundahl; Scott et al.
Assignee(s): DUSA Pharmaceuticals, Inc. (Billerica, MA)A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.
Patent expiration dates:
- January 12, 2038✓
- January 12, 2038
More about Levulan Kerastick (aminolevulinic acid topical)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Side effects
- Dosage information
- During pregnancy
- Drug class: topical photochemotherapeutics
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.